CN1329590A - 治疗产品及其应用 - Google Patents

治疗产品及其应用 Download PDF

Info

Publication number
CN1329590A
CN1329590A CN99813934A CN99813934A CN1329590A CN 1329590 A CN1329590 A CN 1329590A CN 99813934 A CN99813934 A CN 99813934A CN 99813934 A CN99813934 A CN 99813934A CN 1329590 A CN1329590 A CN 1329590A
Authority
CN
China
Prior art keywords
enantiomer
product
application
medicine
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99813934A
Other languages
English (en)
Chinese (zh)
Inventor
H·巴德斯雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Darwin Discovery Ltd
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9826535.8A external-priority patent/GB9826535D0/en
Priority claimed from GBGB9826536.6A external-priority patent/GB9826536D0/en
Priority claimed from GBGB9826537.4A external-priority patent/GB9826537D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of CN1329590A publication Critical patent/CN1329590A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CN99813934A 1998-12-02 1999-12-02 治疗产品及其应用 Pending CN1329590A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9826535.8A GB9826535D0 (en) 1998-12-02 1998-12-02 Therapeutic product and its use
GB9826536.6 1998-12-02
GB9826537.4 1998-12-02
GB9826535.8 1998-12-02
GBGB9826536.6A GB9826536D0 (en) 1998-12-02 1998-12-02 Therapeutic product and its use
GBGB9826537.4A GB9826537D0 (en) 1998-12-02 1998-12-02 Therapeutic product and its use

Publications (1)

Publication Number Publication Date
CN1329590A true CN1329590A (zh) 2002-01-02

Family

ID=27269570

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99813934A Pending CN1329590A (zh) 1998-12-02 1999-12-02 治疗产品及其应用

Country Status (12)

Country Link
EP (1) EP1135361A1 (ja)
JP (1) JP2002531431A (ja)
KR (1) KR20010080364A (ja)
CN (1) CN1329590A (ja)
AU (1) AU1400100A (ja)
BR (1) BR9915873A (ja)
CA (1) CA2350635A1 (ja)
HU (1) HUP0104420A2 (ja)
IL (1) IL142778A0 (ja)
NO (1) NO20012738L (ja)
PL (1) PL347542A1 (ja)
WO (1) WO2000032558A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1164601A (en) 1999-11-09 2001-06-06 Darwin Discovery Limited Therapeutic use and formulation
KR20030059803A (ko) * 2000-10-03 2003-07-10 펜웨스트 파마슈티칼스 컴퍼니 다수의 약학적 활성 물질을 다양한 방출 속도로 전달하는시스템
DE10108122A1 (de) * 2001-02-21 2002-10-02 Gruenenthal Gmbh Arzneimittel auf Basis von Tramadol
WO2003048113A1 (en) 2001-11-30 2003-06-12 Sepracor Inc. Tramadol analogs and uses thereof
JP5269595B2 (ja) 2005-09-09 2013-08-21 アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー １日１回投与用トラゾドン組成物
EP2486921A1 (en) 2007-02-12 2012-08-15 DMI Biosciences, Inc. Reducing Side Effects of Tramadol
CN103936605B (zh) * 2007-05-31 2017-09-01 赛诺维信制药公司 苯基取代的环烷胺作为一元胺再摄取抑制剂
JOP20190251A1 (ar) * 2017-05-31 2019-10-21 Metys Pharmaceuticals AG تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية
WO2019113079A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
EP3720435B1 (en) 2017-12-05 2024-03-06 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
US20220047587A1 (en) * 2018-12-04 2022-02-17 Metys Pharmaceuticals AG Synergistic compositions comprising r-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones and s-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones in a non-racemic ratio
US11160758B2 (en) 2019-06-04 2021-11-02 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
IL131713A (en) * 1997-03-11 2004-08-31 Arakis Ltd Dosage forms comprising separate portions of r- and s-enantiomers
DE19807535A1 (de) * 1998-02-21 1999-08-26 Asta Medica Ag Pharmazeutische Kombinationen mit Tramadol

Also Published As

Publication number Publication date
HUP0104420A2 (en) 2002-08-28
IL142778A0 (en) 2002-03-10
PL347542A1 (en) 2002-04-08
BR9915873A (pt) 2001-08-21
JP2002531431A (ja) 2002-09-24
NO20012738D0 (no) 2001-06-01
WO2000032558A1 (en) 2000-06-08
AU1400100A (en) 2000-06-19
KR20010080364A (ko) 2001-08-22
CA2350635A1 (en) 2000-06-08
EP1135361A1 (en) 2001-09-26
NO20012738L (no) 2001-06-01

Similar Documents

Publication Publication Date Title
Ramael et al. Levetiracetam intravenous infusion: a randomized, placebo‐controlled safety and pharmacokinetic study
RU2140266C1 (ru) Фармацевтическая композиция с регулируемым выделением на основе одной или нескольких фармацевтически приемлемых солей гамма-гидроксимасляной кислоты и способ ее получения
Finnerup et al. Spinal cord injury pain–mechanisms and treatment
Savage Addiction in the treatment of pain: significance, recognition, and management
Schwartz et al. Central insulin administration reduces neuropeptide Y mRNA expression in the arcuate nucleus of food-deprived lean (Fa/Fa) but not obese (fa/fa) Zucker rats
Wu et al. Pre‐incisional epidural ketamine, morphine and bupivacaine combined with epidural and general anaesthesia provides pre‐emptive analgesia for upper abdominal surgery
CN1329590A (zh) 治疗产品及其应用
DE69805202T2 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
Srivastava et al. Rapid loss of efficacy to the antiseizure drugs lamotrigine and carbamazepine: a novel experimental model of pharmacoresistant epilepsy
JP2005527599A (ja) 肥満および摂食障害におけるゾニサミドの使用
Coquoz et al. Central analgesic effects of desipramine, fluvoxamine, and moclobemide after single oral dosing: a study in healthy volunteers
US20120171297A1 (en) Threo-dops controlled release formulation
JP2010505773A (ja) 糖尿病性神経障害における末梢神経の形態機能的回復のための上皮増殖因子の使用
DE69817848T2 (de) Monolithsysteme enthaltend mindestens einer wirkstoff, bestehend aus drei schichten mit unterschiedlichen freisetzungmechanismus
Safarinejad et al. Retracted: Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a double‐blind, placebo‐controlled, randomized study
Mitchell et al. Naltrexone aversion and treatment efficacy are greatest in humans and rats that actively consume high levels of alcohol
US20130230586A1 (en) Treatment of Tinnitus and Related Auditory Dysfunctions
Arneric et al. Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties
Tan et al. Efficacy of intrathecal neostigmine for the relief of postinguinal herniorrhaphy pain
Coutinho et al. The role of CNS NMDA receptors and nitric oxide in visceral hyperalgesia
O’Malley et al. Naltrexone in the treatment of alcohol dependence: Preliminary findings
EP1239858B1 (en) Pharmaceutical for the treatment of convulsive states
Yalín et al. Ketorolac tromethamine in cancer pain
Roger et al. Addition of Benfluorex to Biguanide Improves Glycemic Control in Obese Non–Insulin-Dependent Diabetes: A Double-Blind Study versus Placebo
Hanson et al. Basic neuropharmacological mechanisms of methamphetamine

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication